- Price band
- To be announcedNot in this filing
- Issue size
- 1,33,00,000 sharesFresh issue · amount set with price
- Face value
- ₹10per equity share
- Lot size
- To be announcedMin. investment shown once set
- Anchor biddingMon, 2025
- OpensTue, 2025
- ClosesFri, 2025
- ListingWed, 2025
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue
- Fresh issue
- 1,33,00,000 shares
- Offer for sale
- None
- Total issue
- 1,33,00,000 shares
- Face value
- ₹10
- Listing at
- NSE, BSE
- RHP date
- 20 Aug 2025
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Reservation
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | — | — | 10% |
| Non-institutional investors (NII) | — | — | 15% |
| Qualified institutional buyers (QIB) | — | — | 75% |
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
Fiscal 2025- EPS (basic)
- ₹6.38
- EPS (basic) (Weighted average (Fiscal 2023-2025))
- ₹6.23
- RoNW
- 25.51%
- NAV per share (March 31, 2025)
- ₹20.18
- ROCE
- 21.93%
- Debt to equity
- 0.73
- EBITDA margin
- 26.88%
- PAT margin
- 17.06%
P/E and market cap are calculated once the price band is announced.
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Financials
Standalone, restated · ₹ crore| Period ended | 31 Mar 202512 months | 31 Mar 202412 months | 31 Mar 202312 months |
|---|---|---|---|
| Revenue from operations | 120.29 | 66.58 | 112.88 |
| Total income | 120.46 | 66.69 | 113.12 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| Profit after tax | 20.52 | 9.66 | 5.82 |
| Net worth | 80.42 | 21.03 | 7.37 |
| Reserves and surplus | 40.57 | 5.03 | -4.63 |
| Total assets | 181.30 | 128.00 | 111.55 |
| Total borrowing | 58.35 | 74.56 | 66.39 |
12 months vs 12 months: revenue +80.7%, profit after tax +112.5%.
Source: Red Herring Prospectus dated 20 Aug 2025Updated
About the company
The company manufactures high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs) from its facility in Rajkot, Gujarat. Its range also covers nutraceutical APIs, personal care ingredients and veterinary APIs. It also undertakes custom manufacturing and drug master file development for customers.
- Incorporated
- 2013
- Industry
- Chemicals and Pharmaceutical Intermediates
- CIN
- U24230GJ2013PLC077543
- Website
- anlon.in
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| Punitkumar R. Rasadia | 46.65% | — |
| Meet Atulkumar Vachhani | 23.61% | — |
| Mamata Punitkumar Rasadia | 0.00% | — |
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Capital expenditure for expansion of the manufacturing facility | 30.72 |
| Full or part repayment/prepayment of secured term loan | 5.00 |
| Working capital requirements | 43.15 |
| General corporate purposes | Set with price |
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| Anlon Healthcare LimitedIssuer | ₹6.38 | — | 25.51% | ₹20.18 |
| Kronox Lab Sciences Limited | ₹6.91 | 26.18× | 24.28% | ₹28.26 |
| Acutaas Chemicals Ltd | ₹19.81 | 58.47× | 12.15% | ₹161.24 |
| Supriya Lifeciences Limited | ₹23.35 | 29.27× | 18.86% | ₹123.85 |
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Strengths and risks
Our summary of what the offer document statesStrengths
- Manufactures a broad range of pharmaceutical intermediates, APIs and nutraceutical ingredients.
- Holds drug master file approvals for loxoprofen sodium dihydrate in several overseas markets.
- Serves an established base of domestic and overseas customers.
- Conducts in-house testing and quality control on its product portfolio.
- Has a mainly domestic revenue base, with customers across several Indian states.
Risks
- The manufacturing facility was non-operational for about four months in FY 2023-24 after regulatory directions.
- Revenue depends on a limited number of customers.
- The company has a limited operating history in manufacturing, starting from 2017.
- Equipment for the proposed expansion has not yet been ordered, which may delay implementation.
- The company faces pending GST demands and tax litigation, and its working capital days are high at 308.
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Contacts
Source: Red Herring Prospectus dated 20 Aug 2025Updated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Listing
Source: Red Herring Prospectus dated 20 Aug 2025Updated
After listing
Listing price, day-one high and low, and the change from the issue price (set at allotment) appear here after the shares list on NSE and BSE.
Frequently asked questions
When does the Anlon Healthcare IPO open and close?
According to the Red Herring Prospectus, the issue opens on Tuesday, 26 August 2025 and closes on Friday, 29 August 2025. These dates are tentative.
What is the Anlon Healthcare IPO price band?
The Red Herring Prospectus does not include a price band. The company announces it by advertisement before the issue opens, and this page is updated when it is filed.
Where will Anlon Healthcare shares list?
On NSE and BSE. The tentative listing date is Wednesday, 3 September 2025.
Who is the registrar of the issue?
KFin Technologies Limited (SEBI registration INR000000221). Allotment status is checked on the registrar's website.
How do I check the Anlon Healthcare IPO allotment status?
Search by PAN, application number or DP/client ID on the registrar's website (KFin Technologies Limited), the NSE website or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹30.72 Cr for capital expenditure for expansion of the manufacturing facility, ₹5 Cr for full or part repayment/prepayment of secured term loan, ₹43.15 Cr for working capital requirements, and the rest for the other stated purposes.
Related IPOs
More chemicals and agrochemicals IPOs
- BLS Polymers₹150Listed · 27 Oct – 29 Oct 2026
- Steamhouse India₹81Listed · 9 Sept – 11 Sept 2026
- Sudeep Pharma₹593Listed · 21 Nov – 25 Nov 2025
- Advance Agrolife₹100Listed · 30 Sept – 3 Oct 2025
Also managed by Interactive Financial Services
- Shree Ram TwistexTBAListed · 23 Feb – 25 Feb 2026
- Aritas Vinyl₹47Listed · 16 Jan – 20 Jan 2026
- Aptus PharmaTBAListed · 23 Sept – 25 Sept 2025
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.